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Abstract
Objectives To investigate, using a Dutch model, whether and under
what variables framed for other European countries screening for human
papillomavirus (HPV) is preferred over cytology screening for cervical
cancer, and to calculate the preferred number of examinations over a
woman’s lifetime.
Design Cost effectiveness analysis based on a Dutch simulation model.
Base case analyses investigated the cost effectiveness of more than
1500 different screening policies using the microsimulation model.
Subsequently, the policies were compared for five different scenarios
that represent different possible scenarios (risk of cervical cancer,
previous screening, quality associated test characteristics, costs of
testing, and prevalence of HPV).
Setting Various European countries.
Population Unvaccinated women born between 1939 and 1992.
Main outcome measures Optimal screening strategy in terms of
incremental cost effectiveness ratios (costs per quality adjusted life years
gained) compared with different cost effectiveness thresholds, for two
levels of sensitivity and costs of the HPV test.
Results Primary HPV screening was the preferred primary test over the
age of 30 in many considered scenarios. Primary cytology screening
was preferred only in scenarios with low costs of cytology and in
scenarios with a high prevalence of HPV in combination with high costs
of HPV testing.
Conclusions Most European countries should consider switching from
primary cytology to HPV screening for cervical cancer. HPV screening
must, however, only be implemented in situations where screening is
well controlled.
Introduction
Cytological screening has noticeably reduced the incidence of
cervical cancer in countries with organised screening,
1-3 but in
Europe the disease still accounts for almost 57 000 incident
cases and 25 000 deaths annually.
4 Many European countries
have introduced vaccination against the human papillomavirus
(HPV),
5yetnotallwomenareeligible.
6Insuchwomencervical
cancer screening remains the primary preventive strategy, and
screening in unvaccinated women will continue for several
decades.BecausethecurrentvaccinesagainstHPVdonotfully
cover all the viral types that cause cancer, screening will be
important for vaccinated women. How these women should be
screened requires a specific analysis, which will be carried out
separately and is therefore beyond the scope of this article.
In countries that have a history of cervical cancer screening (or
consider setting up screening), it is being debated whether or
nottoreplacecytologybyHPVscreening.Cytologyhaslimited
reproducibility,
7 and meta-analyses and pooled analyses, both
of cross sectional studies, have established that HPV tests have
highersensitivitythancytologyfordetectinghighgradecervical
intraepithelial neoplasia.
8 9 Despite the clear higher sensitivity
of HPV testing, there is hesitancy about changing to the test,
and so far none of the screening guidelines or national
programmes have actually switched to screening for HPV.
Moreover, recent studies have shown that HPV screening or
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Research
RESEARCHcombined HPV and cytology screening has high negative
predictive values for women who do not have high grade
cervicalintraepithelialneoplasiainthenextscreeninground.
10-13
As a result, joint European data suggested that screening
intervals could be lengthened safely—for example, to six years
among women with a negative HPV test result.
10 Thus a lower
requirednumberofscreeningroundswouldcompensate,atleast
to some extent, for the lower specificity, which is the downside
of HPV testing. The lower specificity is characterised by a
higher positivity rate at every screening round and thus a larger
associatedburdenoffalsepositivetestresultsandovertreatment
of non-progressive cervical intraepithelial neoplasia.
How to weigh these pros and cons of HPV testing compared
with cytology is not straightforward. Key variables are the
quality of cytology screening and the prevalence of HPV
infections relative to the level of risk for cervical cancer. This
also holds for the costs of HPV testing relative to those of
cytology, depending on quality assurance procedures,
concentration of laboratory activities, and the costs of labour.
Since these variables differ between countries, the unique
characteristics of countries can lead to alternative preferred
primary and triage screening tests.
Weinvestigatedthebalancebetweenbenefits,burden,andcosts
ofHPVscreeningcomparedwithcytologyscreeningforvarious
scenariosbasedoncombinationsofvariablesobservedinseveral
European countries. We aimed to show under which realistic
circumstances HPV screening is to be preferred to cytology
screening from a cost effectiveness point of view. In addition,
we calculated the optimal number of screening rounds over a
woman’s lifetime for each scenario, using different cost
effectiveness thresholds.
Methods
Although we do not focus on exploring different triage
strategies, we have included alternatives to ensure that we
compared both primary cytology and primary HPV screening
combined with optimal triage. We considered nine different
strategies: one with primary cytology and cytology triage, four
with primary HPV testing and cytology or a combination of
cytology and HPV triage, and four with primary cytology and
HPV or a combination of HPV and cytology triage (see graphic
representation of screening strategies at http://hdl.handle.net/
1765/31582).Theteststrategiesarebasedonguidelinesorthose
proposed in the literature.
9 14-18
The model
To estimate differences in benefits, harms, and costs between
HPV testing and cytology, we used the microsimulation
screening analysis (MISCAN) model.
19 This model simulates a
large study population with individual life histories, in which
women will, at a certain rate, acquire HPV infections, develop
apreinvasivecervicallesion,andgetcervicalcancer.Somewill
die from the disease. Infections can also be cleared or produce
cervical intraepithelial lesions that will regress. Women can
acquire multiple infections during a lifetime, each with its own
clinical course. The simulation results in an age specific and
calendartimespecificoutputofdiseaseincidenceandmortality.
If the simulated population undergoes screening, some of the
life histories will change. These changes constitute the effects
oftheinterventionandarerepresentedbythenumbersofevents
and stages induced or prevented. The model produces the
number of life years spent in each state as well as the number
of certain events, such as screenings and cervical cancer
diagnoses, in a woman’s lifetime. We calculated a woman’s
quality adjusted life years (QALYs) as the weighted sum of the
number of years spent in each of these states, using utility
weights, which can range from 0 to 1; for some events, a fixed
utility (which can be negative) is added to this weighted sum.
The total effectiveness of screening (QALYs gained and life
years gained) is determined as the difference in the number of
life years gained/QALYs between the situation with screening
andthesituationwithoutscreening.Weusedasimilarapproach
to determine the net costs of screening.
Model specifications: demography,
epidemiology, and clinical course
TheMISCANcervixmodelwasoriginallydevelopedtosimulate
the Dutch situation.
19 This model is validated on detailed data
available from the Netherlands, ensuring a coherent model of
the clinical course of cervical cancer. Given that data are
insufficient to test the clinical course model for each country,
itisreasonabletoassumethattransitionprobabilitiesanddwell
times of preclinical stages are similar between countries, while
varying the disease incidence to reflect different background
risks. We varied other variables only if critical for the decision
analyses, leaving those that will not significantly influence the
outcome, as in the Dutch model. So, although we adjusted the
modeltotherangeincervicalcancerlevelsobservedinEurope,
we assumed that the age distributions of cervical intraepithelial
neoplasia and cervical cancer were comparable in Europe and
we estimated these age distributions based on the Dutch
situation. This approach was also used for personal
characteristics
20 and hysterectomy rates.
21 (See description of
the data on which the model was calibrated at http://hdl.handle.
net/1765/31582)
Disease is subdivided into seven sequential stages: high risk
HPV infection (infection caused by an HPV type that can cause
cancer and that can be detected by the HPV test), three
preinvasive stages (cervical intraepithelial neoplasia grades I,
II, and III), and three invasive stages (International Federation
of Gynecology and Obstetrics (FIGO) stages IA, IB, and II or
worse). Preinvasive and FIGO IA stages can be diagnosed by
screening only, because no symptoms will develop, whereas
stages IB and II or worse can also be clinically diagnosed. The
disease is usually not progressive; in the model, most HPV
infections will clear without ever resulting in neoplasia, and
lesions in the preinvasive stages can regress spontaneously. If
no mortality occurs from other causes, undetected preclinical
invasive neoplasia will always progress to clinical cancer. In
cervicalintraepithelialneoplasiagradesIandIIahighriskHPV
infection may or may not be present; if no high risk infection
ispresent,thelesionwillalwaysregress.Cervicalintraepithelial
neoplasia grade III and invasive stages can only develop if a
highriskHPVinfectionispresent.(Seedurationsofthedifferent
stages at http://hdl.handle.net/1765/31582.)
Giventhatourresearchquestionconcernsunvaccinatedwomen,
we used a population model that simulated the life histories of
eight million women born from 1939 to 1992. Women born
before 1939 are too old to attend screening after 2009, and
women born after 1992 are eligible for HPV vaccination.
Because of the expected lower risk of cancer in vaccinated
women,aseparatescreeningstrategywillhavetobedetermined
for vaccinated cohorts in the future. We assumed that the
simulatedscreeningpoliciesstartedin2009andcontinueduntil
allsimulatedwomenhadcompletedtheirscreeningprogrammes.
Information on the screening pattern before 2009 was obtained
from the Dutch national pathology database, assuming that the
variationinscreeningactivitiesinEuropewillhaveanegligible
influenceontheeffectivenessofthescreeningprogrammeafter
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RESEARCH2009. We derived the relative risks per birth cohort from an
age-period-cohort analysis of cervical cancer mortality.
22
Assumptions for screening and treatment
Weassumedthat10%ofthepopulationneverattendsscreening
andhasathreetimeshigherbackgroundriskforcervicalcancer
than the 90% of potential attenders—that is, the high risk and
low risk strata.
23 From 2009 onwards we assumed the rate of
potential attenders to be 80% for all primary screenings; in the
model, follow-up screenings and referrals for colposcopy are
always attended.
The HPV test uses the same type of cervical sample as does the
cervical smear test. However, instead of placing cervical cells
on a glass microscope slide, as in liquid based cytology, they
are placed in a vial of liquid preservative. Testing for HPV is
typically done using automated molecular amplification or
hybridisation techniques. The test measures the presence of 13
high risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, and 68). Positive samples were those that attained or
exceeded the threshold of 1.0 pg/mL of HPV DNA.
Table1⇓presentstheassumptionsforscreening.Thesensitivity
of the HPV test was estimated at 95% for a high risk HPV
infection.
24 Because uncertainty exists about the sensitivity of
theHPVtest
8wealsoassumedasensitivityof90%.Weassumed
the sensitivity of the smear test (that is, the probability that the
result is atypical squamous cells of undetermined significance
or worse) for different disease stages to be 40% for cervical
intraepithelialneoplasiagradeI,50%forcervicalintraepithelial
neoplasiagradeII,and75%forcervicalintraepithelialneoplasia
III or worse.
25 Because several triage strategies distinguish
between a smear showing atypical squamous cells of
undeterminedsignificanceorlowgradesquamousintraepithelial
lesionandasmearwitharesultworsethanlowgradesquamous
intraepithelial lesion, we needed to specify the probability of a
result worse than low grade squamous intraepithelial lesion for
each stage. The sensitivity of testing for at least high grade
squamous intraepithelial lesion (that is, the probability of low
grade squamous intraepithelial lesion or worse) was assumed
to be 4% for cervical intraepithelial neoplasia grade I, 19% for
cervical intraepithelial neoplasia grade II, 47% for cervical
intraepithelial neoplasia grade III, and 49% for cervical cancer.
The specificity of the smear test was estimated to be 98.5% in
thecaseofhighquality,basedonthefalsepositiverateofsmear
test results in the Dutch screening programme. The specificity
of the HPV test for HPV infections was assumed to be 100%,
becauseaneventuallackofspecificityismodelledbyincluding
fast clearing infections.
Detectionandtheassociatedmanagementofpreinvasivelesions
(including retreatment in some cases) were assumed to lead to
a 100% cure rate. A woman can, however, develop a new HPV
infection and neoplasia after treatment. For screen detected
invasive cancers, the survival was modelled as a reduction in
theriskofdyingofcervicalcancercomparedwiththatofdying
if the disease had been clinically diagnosed; this reduction for
FIGO stages IA, IB, or II or worse was 80%, 60%, or 20%,
respectively. As an example, this results in an average five year
survival of about 97% for (screen detected) stage IA.
22
Assumptions for costs and utilities
Table 2⇓ presents the costs and utilities used in the analysis.
Screening costs include the process used to invite women, the
timeandtravelrequiredtoattendscreening,thetest,cytological
evaluation or HPV analysis, and registration in the pathology
database. We derived the costs of screening, diagnosis, and
treatmentproceduresfordetectedpreinvasivelesions,ofprimary
treatment of invasive cervical cancer, and of treatment and
palliative care for advanced cervical cancer from cost studies
in the Netherlands.
26 In the model, a small (psychological) loss
in quality of life is assumed for attending a screen (including
waitingfortheresult)andforbeingintriage(includingattending
follow-upscreenings)afterapositiveprimarytestresult.Larger
losses in quality of life are assumed for receiving a diagnosis
ofcervicalintraepithelialneoplasiaorcancerandtreatmentand
forhavingaterminalstageofcervicalcancer.Webasedutilities
on nationally and internationally published data.
22 27 28
Cost effectiveness analyses
To ensure that the chosen age range and combinations of
screening intervals would not affect the performance of HPV
testingrelativetotheperformanceofcytologytesting,wevaried
the ages at which screening takes place. We considered all
screening policies with starting ages of 25, 27, 30, or 32 that
comprise at least three and at most 10 screenings and that have
an interval of at least three years and at most 10 years; we did
not simulate policies that include screenings over the age of 70
years. In total we simulated 1539 policy-strategy combinations
(nine strategies multiplied by 171 policies).
In the results we account for the costs and effects of screening
until all simulated women died. The total costs consist of those
for invitations, primary and follow-up screenings, treatment of
preinvasive and invasive cancer, and terminal care. We present
the effects as the numbers of life years gained and QALYs
gained by screening for cervical cancer. The cost effectiveness
calculations were carried out from the adjusted societal
perspective(notaccountingforproductivitylossesduetoillness
and death). To convert future costs and health effects to the
present, we discounted both costs and effects (life years and
utility losses) at a rate of 3% using 2009 as a reference year.
Sensitivity analyses
In the sensitivity analyses we compared all policy-strategy
combinations simulated in the base case analysis for five
different scenarios that represent contrasting real life situations
(table 3⇓). We based the scenarios on differences in
characteristics observed between European countries that are
relevant when HPV screening is compared with cytology
screening:theriskofcervicalcancer,previousscreening,quality
associated test characteristics, costs of the test, and prevalence
of HPV. For one scenario (last column in table 3), with low
costs for cytology, we also considered more intensive policies
that comprised 11 to 20 screenings, including intervals of one
and 10 years.
Cervical cancer risk—To cover the range of mortality levels
in different European countries we assumed three background
risks of cervical cancer related mortality; the risk of dying of
cervical cancer in a situation without screening—namely, 5.0,
7.5, and 10 deaths per 100 000 life years (table 1).
Previousscreening—Theexistenceofascreeningprogramme
before 2009 varied between European countries. Therefore we
considered all simulated situations with and without previous
screening (table 1). After taking into account past screening,
the corresponding simulated mortality for invasive cervical
cancerin2009was2.0,3.0,or4.0deathsper100000lifeyears.
Quality associated test characteristics—We varied the
assumptions for screening to account for observed differences
between countries or for uncertainties (table 1). For scenarios
withhigherqualitysmeartestsweassumedthesamesensitivities
as in the base case analysis. For scenarios with lower quality
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e670 doi: 10.1136/bmj.e670 (Published 5 March 2012) Page 3 of 14
RESEARCHsmear tests we assumed sensitivities of 32% for cervical
intraepithelialneoplasiagradeI,40%forcervicalintraepithelial
neoplasiagradeII,and60%forcervicalintraepithelialneoplasia
grade III or worse. For these scenarios the sensitivity of testing
for at least high grade squamous intraepithelial lesions was
assumedtobe3%,15%,and38%,respectively.Thespecificity
for higher quality tests was estimated to be 98.5%, based on the
rate of false positive smear test results in the Dutch screening
programme. In case of low quality tests, the specificity was
estimated to be 97%.
Costs of the test—To consider differences in screening costs
across Europe we also halved the total costs of cytology. Two
possibilities were analysed for the laboratory costs of the HPV
test: €21.36 (£17.86; $28.00) and €33.23.
29
Prevalence of HPV—Given that in the model the increase in
the risk of being infected with HPV is proportional to the
increase in the risk of getting cervical cancer, the prevalence of
HPV in the total population is 3% for a background risk of 5.0
deaths per 100 000 life years, 4% for a risk of 7.5 deaths per
100 000 life years, and 5% for a risk of 10.0 deaths per 100 000
life years. In some countries, however, the ratio between
prevalence of HPV and risk of cervical cancer is higher. To
represent these countries in scenarios with a higher prevalence
ofHPVweadditionallydoubledthenumberoftriagetestsafter
primary testing for HPV.
Results
For the six scenarios that reflect the differing situations for
cervical cancer screening in Europe, the predicted costs and
QALYs gained were determined for 1539 simulated screening
strategies. To illustrate the influence of the different scenarios
(base case and five scenarios) on the results of screening, the
undiscounted results of three efficient screening strategies are
presented(table4⇓):primarycytologywithcytologytriageand
primary HPV screening with two times cytology triage and
sensitivity of 90% or 95%. In this example all women were
screened from age 30 years and at intervals of five years until
age 60 years. The number of triage screens increased with
background risk and, more clearly, with a lower specificity of
primarycytologyor,inthecaseofprimaryHPVscreening,with
a higher prevalence of HPV (table 4). The numbers of cervical
intraepithelial neoplasia grade II or III lesions, cases of cancer,
and deaths from cervical cancer increased with the background
risk for all screening strategies. A low sensitivity of the primary
test resulted in a decrease in the number of detected cervical
intraepithelial neoplasia grade II or III lesions and an increase
in the number of cases of cancer and deaths (table 4).
Todeterminesocalledefficientstrategies,thosethatweremore
costly and less effective than others were ruled out as
non-efficient by simple dominance. Strategies that were more
costly and less effective than a combination of other strategies
were ruled out as non-efficient by extended dominance. The
principle of extended dominance is applied in incremental cost
effectiveness analysis to eliminate from consideration those
strategies for which the costs and benefits are improved by a
mixed strategy of two alternatives.
30
The results show that primary HPV screening was preferred
over primary cytology screening in most of the scenarios (table
5⇓). In the two scenarios with a high prevalence of HPV,
primary cytology screening was preferred only if higher costs
for HPV screening were also assumed. In the scenario with low
costs for cytology, primary cytology was preferred,
notwithstanding the lower sensitivity and specificity that
accompanied the lower costs. This result was independent of
thebackgroundriskintherangeconsidered(resultsnotshown).
The figure⇓ shows the efficient frontier of the scenario of an
average background risk and high prevalence of HPV for
primary cytology screening and for primary HPV screening. It
showshowprimarycytologyscreeningisdominatedbyprimary
HPV screening when the costs of HPV screening are low, and
how primary HPV screening is dominated by primary cytology
screening when the costs of HPV screening are high. In
comparison, the efficient frontiers for the scenario of high risk
with no past screening and a low sensitivity, specificity, and
costofcytology(seefigureathttp://hdl.handle.net/1765/31582)
show how primary HPV screening is dominated by primary
cytology screening. This figure also presents the number of
examinations during a woman’s lifetime. It shows that for the
samenumberofQALYsgainedfiveHPVtestscouldbecarried
outduringawoman’slifetime,comparedwitheightcytological
tests. In this scenario, however, eight times primary cytology
is cheaper.
The intensity at which screening would still be cost effective
mainly depended on the background risk of the scenario and on
the cost effectiveness threshold applied (table 6⇓). In scenarios
with low background risk and with past screening (including
base case scenario), three examinations during a lifetime were
cost efficient at a threshold of €20 000 per QALY gained and
five at a threshold of €50 000 per QALY gained. On the other
hand, in the case of a high background risk and no past
screening,13cytologyexaminationsduringalifetimewerecost
efficient at a threshold of €20 000 per QALY gained and 20 at
the €50 000 threshold. The age range increased accordingly
from30-46yearsto27-65years(table6).Thescreeninginterval
decreased from eight to three years.
An online calculation tool (available at http://hdl.handle.net/
1765/31582) can be used to calculate the cost effectiveness of
the three efficient screening strategies from table 4, with
different values for the specificity of cytology, the prevalence
of HPV, the costs of screening and treatment, and the utilities
lost for different stages of the screen process.
Discussion
PrimaryscreeningforHPVispreferredinmanyofthescenarios
that would correspond to cervical cancer screening in various
European countries. For countries with a high prevalence of
HPVandhighcostsfortheHPVtest,however,primarycytology
screening is preferred over primary HPV testing. Since
population based primary HPV screening trials or programmes
are not yet implemented in most European countries, reliable
estimates for the prevalence of HPV are often not available and
it is not clear whether the situation of high prevalence of HPV
and high costs for the HPV test is common in Europe. Based
on the results from trials of HPV screening and the reported
incidence of cervical cancer, this situation seems the case in,
for example, the United Kingdom and Italy.
31-33 Regardless, the
finding indicates that it is important to organise primary HPV
screening in such a manner that the costs of the test are low.
This can be achieved by concentrating the large numbers of
HPV DNA tests in large laboratories to achieve economy of
scale effects, such that the costs per test are lower if more test
are analysed.
Primarycytologicalscreeningisalsopreferredincountrieswith
low cytology screening costs, even when accounting for lower
quality in terms of lower specificity and sensitivity of low cost
cytology. Cytology with low costs, carried out by
cytotechnicians, reflects low labour costs and is therefore
relevantforsomeeasternEuropeancountries,suchasRomania,
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RESEARCHBulgaria, the Slovak Republic, and Latvia.
34 It is recommended
that countries with a high risk of cervical cancer or a high cost
effectiveness threshold screen more intensively (that is, begin
screening at a younger age, end at an older age, and have a
shorter interval between the scheduled examinations) than
countries with a low risk or a low cost effectiveness threshold,
ranging from three to 20 examinations during a lifetime.
Comparison with other studies
Other published cost effectiveness analyses on HPV screening
evaluated the combination of smear tests and HPV tests as
primary screening and some studies evaluated HPV tests alone
as the primary test. The publications provided costs and effect
estimates, and incremental cost effectiveness ratios based on a
comparisonwithscreeningprogrammesusingsmeartests,with
intervals of 1, 2, 3, and 5 years. The publications differ in many
respects:theyinvestigateddifferentscreeningstrategiesinterms
of the applied tests or test combinations, screening intervals,
and target ages. The studies also differed in methodological
approach (type of model, analytical time horizon, perspective
oftheanalysis,andcostcalculations).Asaresulttheconclusions
are heterogeneous: three analyses support primary HPV
screening in a conventional cytology setting,
29 35 36 one supports
it in a liquid based cytology setting but does not support it in a
conventionalcytologysetting,
37onesupportsitinaconventional
settingbutdoesnotsupportitinaliquidbasedcytologysetting,
38
and one does not support it in a conventional setting.
28 We
quantified the importance of various levels and combinations
of the sensitivity, specificity, and costs of each of the tests
compared.
Limitations of the study
Alimitationofouranalysisisthatwedidnotconsiderstrategies
that differ by age group. Some have suggested that screening
for HPV DNA is not an acceptable screening test before age 30
years.
39 It was also shown from a cost effectiveness point of
viewthatprimarycytologyscreeningispreferredundertheage
of 30 and primary HPV testing over the age of 30.
40 The only
cost effective policy in our results with screening under the age
of 30 was primary cytology screening (table 6). In addition,
HPV screening in young women at an increased cut-off point
for a positive HPV test of 10 pg/mL HPV DNA could be an
option.
41
Weadaptedthemodeltoparticularcountrysituationsbyvarying
epidemiological (background risk and past screening) and
screeningcharacteristics(testsensitivity,specificity,andcosts).
The scenario of average background risk and high prevalence
of HPV, for example, is based on the situation in Italy and the
United Kingdom; the scenario of average background risk and
low test sensitivity and specificity of cytology is based on the
situation in Germany; the scenario of low risk, low specificity
of cytology is based on the situation in Finland; the scenario of
high risk, high prevalence of HPV the situation in Denmark;
and the scenario of high risk, no past screening, and low
sensitivity, specificity, and costs of cytology the situation in
Romania. Some of the variables that were not varied in the
sensitivityanalyseswerestillbasedonDutchdata.Forinstance,
in addition to the incidence of cervical cancer (which was
varied), the age pattern of the incidence (which was not varied)
may differ between countries.
42 In some countries the peak age
specific incidence in setting of no screening was estimated to
occur at an older age than the 45 years estimated for the
Netherlands.
43 Also, personal characteristics were not varied.
Noneofthesedifferenceswill,however,influencethepreferred
typeofprimaryscreentestinaspecificcountry,whichwaswhy
we did not include them in the list of adjusted variables.
Information on the prevalence of HPV compared with the risk
of cervical cancer in different countries is lacking. We used the
percentage of HPV positive women in European randomised
controlled trials of cervical cancer screening, with HPV testing
as the primary screen
32 compared with the incidence of cervical
cancer in these countries. The prevalence of HPV measured in
the randomised controlled trial setting may not be exactly
representative of the real situation in a specific country. But
eveniftheassumptionswehavemadeinthesensitivityanalyses
are not correct, it does show the probable effect of the HPV
prevalence:cervical cancer incidence ratio.
Weassumedthat10%ofthepopulationneverattendsscreening
andhasathreetimeshigherbackgroundriskforcervicalcancer
than the 90% potential attenders (the high risk stratum and the
low risk stratum), based on international data when mass
screening for cervical cancer started.
23 If this healthy screener
selection is not applicable (anymore), we could have
underestimated the effect of screening and thus also the cost
effectiveness.Nevertheless,thepreferredtypeofprimaryscreen
test would again not change. Furthermore, we assumed that
follow-up screenings and referrals for colposcopy are always
attended. This assumption could have led to an overestimation
oftheeffectofprimaryHPVscreeningcomparedwithcytology
screening,becausemorewomenarereferredforfollow-uptests
in cases of primary HPV screening. We found that if an
attendance rate of 90% at triage was assumed in the base case
situation, primary HPV testing is still the most cost effective
option.
44
TheuseofQALYsasanoutcomemeasureincosteffectiveness
modelling is recommended by the Panel of Cost-Effectiveness
in Health and Medicine,
45 but depends on the reliability of
quantificationofqualityoflifeaspectsofscreeningandcervical
cancer. Given that HPV screening has a higher positive rate
than cytology, our conclusion that primary HPV screening is
preferred to cytology screening is sensitive to the loss of utility
associated with a triage episode (until referral to screening or
colposcopy) after a positive HPV test result. We found, for
example, in the base case situation that if the utility loss
associated with follow-up screenings was the equivalent of
seven days of life instead of two days of life per year spent in
triage, primary cytological screening with HPV triage would
be more cost effective than primary HPV testing.
44
Men were not included in our model. Men do influence the
prevalence of HPV in the female population, owing to sexual
interaction. Since HPV screening has a higher sensitivity, more
HPV infection can in theory be removed from the population.
So the chance of becoming infected with HPV could be lower
in the case of HPV screening. Nevertheless, this effect will be
small, and including men would probably not result in other
outcomes.
Policy recommendations
We showed that primary HPV screening is to be preferred in
mostEuropeansettings.However,implementingHPVscreening
insituationswherescreeningisnotwellcontrolledcarriesrisks
that may be unacceptable. Frequent screening at a young age
decreasestheprogramme’sspecificitygiventhateveryscreening
round adds to false positive test results (that is, the detection of
non-progressive HPV infections or cervical intraepithelial
neoplasia lesions), and screening at a young age detects many
transient infections and abnormalities. Overtreatment of young
womenthatmayoccurwithfalsepositivetestresults(bothwith
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RESEARCHHPV testing and cytology) can have adverse health and
pregnancy outcomes. Uneven distribution of HPV screening
over the population, with frequent screening at young age, may
affect the balance between benefits on the one hand and harms
and costs on the other. In addition, HPV screening should be
organised in such a way that the procedures are carried out in
large centres to monitor the quality of the screening and to
benefit from economies of scale. This is especially the case for
HPV testing, which can be automated to a large extent, and
where economies of scale will make a considerable difference
to costs.
Conclusion
We carried out an extensive simulation study, using a Dutch
model,toinvestigateunderwhichrealisticEuropeanconditions
HPVtestingistobepreferredtocytologyscreeningasaprimary
testforthedetectionofcervicalcancer.PrimaryHPVscreening
was preferred in most of the scenarios considered. Primary
cytology screening was only preferred in scenarios with low
costsofcytologyandinscenarioswithhighprevalenceofHPV
in combination with high costs of HPV testing. Therefore most
European countries should seriously consider switching from
primary cytology to HPV screening. Such screening must,
however, only be implemented in situations where screening is
already well controlled.
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RESEARCHTables
Table 1| Model inputs: variables that were varied between scenarios, and values considered. Values are percentages unless stated otherwise
Alternative values Variables
5.0/7.5/10 per 100 000 Background risk of cervical cancer mortality
Yes/No Past screening (cytology)
Sensitivity (probability of at least ASCUS) of cytology for CIN grade
25:
40/32 CIN grade I
50/40 CIN grade II
75/60 CIN grade III or worse
Probability of at least HSIL for CIN grades:
4/3 CIN grade I
19/15 CIN grade II
47/38 CIN grade III or worse
97/98.5 Specificity of cytology (for CIN grade I or worse)
90/95 Sensitivity of HPV test (for high risk HPV infection)
24
Low/High Prevalence of HPV in CIN grade I or less*
21/33 Laboratory costs (€) HPV screening
26/52 Total cost (€) cytology
20 000/30 000/50 000 per QALY gained Threshold value (€) for cost effectiveness
€1.00 (£0.84; $1.31).
See table 2 for rounded up values for laboratory costs of screening and total cost of cytology.
ASCUS=atypical squamous cells of undetermined significance; CIN=cervical intraepithelial neoplasia; HSIL=high grade squamous intraepithelial lesion; QALY=quality
adjusted life year.
*Depends on background risk of cervical cancer mortality. On top of increased HPV prevalence associated with a higher background risk, to account for the
possibility of a country with a high prevalence of HPV, the number of women with a positive HPV test result and without cytological abnormalities was multiplied
by a factor of 2. If the background risk was 5 deaths per 100 000 life years, the mean prevalence of HPV in the total population would be 6% in the case of high
prevalence and 3% in the case of low prevalence; if the background risk was 7.5 deaths per 100 000 life years, the mean prevalence in the total population would
be 8% or 4%; and if the background risk was 10 deaths per 100 000 life years, the mean prevalence in the total population would be 10% or 5%.
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RESEARCHTable 2| Model inputs: costs and level and duration of loss of utilities for events and health states that are induced or prevented by screening
(costs are in 2008 prices)
Utilities lost
Costs (€) Model inputs Duration Level
— 0 4.65 Invitation
2 weeks 0.006 Primary cytology screening:
21.36 Laboratory costs of test
11.02 Organisation
11.54 General practitioner costs
5.90 Time and travel
2.04 Programme costs
25.94/51.88† Total
Time since last test* 0.006 Repeat cytology test:
21.79 General practitioner costs
26.04 Laboratory costs
5.90 Time and travel
2 weeks 0.006 Primary HPV screening:
33.23/21.36 Laboratory costs of test
11.02 Organisation
11.54 General practitioner costs
5.90 Time and travel
2.04 Programme costs
Time since last test 0.006 Repeat HPV test:
21.79 General practitioner costs
33.23 Laboratory costs
5.90 Time and travel
Diagnoses and treatment
Preinvasive CIN:
0.5 year 0.005 279 False positive
0.5 year 0.03 869 Stage I
1 year 0.07 1287 Stage II
1 year 0.07 1507 Stage III
Invasive cancer (FIGO stages):
5 years 0.062 4935 IA
5 years 0.062 11 703 IB
5 years 0.28 11 535 II or worse (screen detected)
5 years 0.28 10 773 II or worse (clinically detected)
1 month 0.712 26 209 Terminal care
€1.00 (£0.84; $1.31).
CIN=cervical intraepithelial neoplasia; FIGO=International Federation of Gynecology and Obstetrics.
*Two weeks, if a woman is invited for a repeat test immediately after a positive primary test result; six months; or 12 months.
†To consider differences in screening costs across Europe, total costs were also halved.
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RESEARCHTable 3| Base case scenario and five scenarios of realistic combinations of variables. The scenarios were based on differences in
characteristics observed between European countries
Scenarios in sensitivity analyses
Base case
scenario (low
risk) Possibilities Parameters
High risk; no past
screening; low
sensitivity,
specificity, and costs
of cytology
High risk, high
HPV prevalence
Low risk, low
specificity of
cytology
Average risk, low
sensitivity and
specificity of
cytology
Average risk,
high HPV
prevalence
No Yes Yes Yes Yes Yes Yes/No Past screening
10.0 10.0 5.0 7.5 7.5 5.0 5.0/7.5/10.0 per
100 000
Risk without screening
Low (5) High (10) Low (3) Low (4) High (8) Low (3) Low/High* Prevalence (%) of
HPV in total
population
Cytology:
60 75 75 60 75 75 60/75† Sensitivity (%)
97 98.5 97 97 98.5 98.5 97/98.5 Specificity (%)
26 52 52 52 52 52 26/52 Total costs (€)‡
HPV test:
21/33 21/33 21/33 21/33 21/33 21/33 21/33 Laboratory costs (€)§
90/95 90/95 90/95 90/95 90/95 90/95 90/95 Sensitivity (%)§
Risk refers to background risk of cervical cancer mortality throughout.
€1.00 (£0.84; $1.31).
*Prevalence is 97% for countries with background risk of 5.0 per 100 000 life years, 96% for background risk of 7.5 per 100 000 life years, and 95% for background
risk of 10.0 per 100,000 life years. To account for possible high prevalence in a country the number of women with a false positive test result was multiplied by a
factor of 2.
†Sensitivity for all CIN (cervical intraepithelial neoplasia) stages (see table 1) was varied with same relative change (60%:75%); sensitivity for CIN III or worse was
given as example.
‡Including organisation costs.
§Both possibilities analysed because of uncertainty about these parameters.
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RESEARCHTable 4| Example of undiscounted results of primary cytology screening with cytology triage (see scenario 5 in web extra figure on bmj.com)
and two type of primary human papillomavirus (HPV) screening and cytology triage with varying sensitivity of HPV screening (scenario 3
in web extra). Women are screened seven times during a lifetime, starting at age 30, and at intervals of five years
Deaths from cervical
cancer (per 100 000
life years)
Cancer cases (per
100 000 life years)
CIN II or III lesions
(% of first primary
smears)
Triage screens (% of
first primary smears)
Mean No of primary
screens per simulated
woman* Scenarios
Primary cytology screening with cytology triage
2.6 5.7 0.3 3.3 2.13 Base case (low risk):
3.9 8.5 0.4 3.6 2.13 Average risk, high HPV prevalence
4.4 9.6 0.4 6.2 2.13 Average risk, low sensitivity and specificity
of cytology
2.6 5.7 0.3 6.1 2.13 Low risk, low specificity of cytology
5.2 11.2 0.6 3.9 2.13 High risk, high HPV prevalence
7.2 15.9 0.6 6.4 2.13 High risk, no past screening, and low
sensitivity, specificity, and cost of cytology
Primary HPV screening with two times cytology triage, sensitivity of HPV screening 90%
2.5 5.3 0.3 4.8 2.13 Base case (low risk):
3.7 7.9 0.4 13.3 2.13 Average risk, high HPV prevalence
3.9 8.6 0.4 7.3 2.13 Average risk, low sensitivity and specificity
of cytology
2.5 5.3 0.3 4.8 2.13 Low risk, low specificity of cytology
4.9 10.5 0.6 17.6 2.14 High risk, high HPV prevalence
6.4 14.2 0.7 9.9 2.13 High risk, no past screening, and low
sensitivity, specificity, and cost of cytology
Primary HPV screening with two times cytology triage, sensitivity of HPV screening 95%
2.4 5.2 0.3 5.1 2.13 Base case (low risk):
3.6 7.8 0.4 14.0 2.14 Average risk, high HPV prevalence
3.9 8.5 0.4 7.7 2.13 Average risk, low sensitivity and specificity
of cytology
2.4 5.2 0.3 5.1 2.13 Low risk, low specificity of cytology
4.8 10.3 0.6 18.5 2.14 High risk, high HPV prevalence
6.3 13.9 0.7 10.3 2.13 High risk, no past screening, and low
sensitivity, specificity, and cost of cytology
Risk refers to background risk of cervical cancer mortality throughout.
*Values are less than 7 owing to non-attendance and because mean age of simulated women is 40 years in 2009.
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RESEARCHTable 5| Preferred primary test for different levels of sensitivity of human papillomavirus (HPV) screening (90% v 95%), and laboratory
costs of HPV test (€21 v €33)
Laboratory costs HPV test €33 Laboratory costs HPV test €21
Scenarios 95% sensitive 90% sensitive 95% sensitive 90% sensitive
HPV HPV HPV HPV Base case (low risk):
Cytology Cytology HPV HPV Average risk, high HPV prevalence
HPV HPV HPV HPV Average risk, low sensitivity and specificity of cytology
HPV HPV HPV HPV Low risk, low specificity of cytology
Cytology Cytology HPV HPV High risk, high HPV prevalence
Cytology Cytology Cytology Cytology High risk, no past screening, and low sensitivity, specificity, and
cost of cytology
Results were consistent for incremental cost effectiveness thresholds between €20 000 and €50 000 per QALY gained.
€1.00 (£0.84; $1.31).
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RESEARCHTable 6| Number of screening rounds and age ranges of preferred strategy (see table 5) per threshold of cost effectiveness* where sensitivity
of human papillomavirus (HPV) screening is 90% or 95%, and laboratory costs of HPV test are €21 or €33
Laboratory costs HPV test €33 Laboratory costs HPV test €21
Scenarios
95% sensitivivity 90% sensitivity 95% sensitivity 90% sensitivity
50 000 30 000 20 000 50 000 30 000 20 000 50 000 30 000 20 000 50 000 30 000 20 000
4 (30-54) 3 (30-46) 3 (30-46) 5 (30-54) 3 (30-46) 3 (30-46) 5 (30-62) 4 (30-54) 3 (30-46) 5 (30-58) 4 (30-54) 3 (30-46) Base case (low
risk)
8 (30-65)† 6 (30-55)† 5 (30-50)† 8 (30-65)† 6 (30-55)† 5 (30-50)† 8 (27-69) 5 (30-58) 4 (32-56) 8 (25-67) 5 (30-60) 4 (30-54) Average risk,, high
HPV prevalence
7 (30-66) 5 (30-58) 4 (30-54) 6 (30-65) 5 (30-58) 3 (32-46) 7 (30-66) 5 (30-58) 4 (32-56) 8 (30-65) 5 (30-58) 4 (32-53) Average risk, low
sensitivity and
specificity of
cytology
5 (30-54) 4 (30-46) 3 (30-46) 5 (30-58) 4 (30-46) 3 (30-46) 5 (30-65) 4 (30-54) 3 (30-46) 5 (30-58) 4 (30-54) 3 (30-46) Low risk, low
specificity of
cytology
10 (30-66)
†
7 (30-60) † 6 (30-55) † 10 (30-66)
†
7 (30-60) † 6 (30-55) † 9 (30-66) 7 (30-58) 5 (32-56) 10 (30-65) 7 (30-58) 5 (32-53) High risk, high
HPV prevalence
20
(27-65)†
17
(30-62)†
13
(30-66)†
20
(27-65)†
17
(30-62)†
13
(30-66)†
20
(27-65)†
17
(30-62)†
13
(30-66)†
20
(27-65)†
17
(30-62)†
13
(30-66)†
High risk, no past
screening, low
sensitivity,
specificity, and
cost of cytology
€1.00 (£0.84; $1.31).
*Costs (€) per QALY gained.
†Primary cytology based programme.
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RESEARCHFigure
Representation of simulated efficient frontiers of scenario of an average background risk and high prevalence of HPV when
assuming only primary cytology screening or only primary HPV screening for different assumptions about HPV testing (90%
or 95% sensitivity and €52 or €64 total costs). Each mark represents an efficient programme with different screening ages.
Costs (€000s) and effects (000s) of quality adjusted life years (QALYs) gained, 3% discount rate for costs and effects
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